SMTI Stock Analysis: Buy, Sell, or Hold?
SMTI - Sanara MedTech Inc. Common Stock
$23.32
-1.61 (-6.44%)
▼
5d:
-5.95%
30d:
+8.44%
90d:
+32.47%
HOLD
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 12, 2026
28d
Get Alerted When SMTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SMTI trades at premium valuation expecting 9.5% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: SMTI trades at premium valuation expecting 9.5% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$26.29
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$16.32
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SMTI is currently trading at $23.32, which is considered fair relative to its 30-day fair value range of $21.88 to $24.36. From a valuation perspective, the stock is trading at a premium (Forward PE: 46.1) compared to its historical average (35.2). At these levels, the market is pricing in 9.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SMTI is showing sideways momentum. The price is approaching resistance at $23.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 6.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.33 (+37.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SMTI is showing sideways momentum. The price is approaching resistance at $23.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 6.4% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.33 (+37.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$21.88 -
$24.36
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.4%)
- BULLISH: Trading 37.8% below Wall St target ($34.33)
- NEUTRAL: Trading at premium valuation - market expects 9.5% growth which is achievable
- CAUTION: Recommendation downgraded due to -5.9% 5-day decline
Trading Range Analysis
30-Day Trading Range
$21.88 -
$24.36
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$20.91
Resistance Level
$23.92
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
46.15
Wall Street Target
$34.33
(+37.8%)
Revenue Growth (YoY)
18.6%
Profit Margin
-31.2%
Valuation Premium vs History
+9.5% premium
PE vs Historical
46.2 vs 35.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+9.5%
(market-implied from PE analysis)
1-Year Target
$27.29
(+10%)
2-Year Target
$29.88
(+20%)
3-Year Target
$32.72
(+31%)
3-Yr Target (if PE normalizes)
(PE: 46→35)
PE COMPRESSION
$24.96
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 46.1, Growth: 200.0%)
$84.11
(+238%)
Base:
(SPY PE: 21.8, Growth: 200.0%)
$39.69
(+59%)
Bear:
(PE: 18.5, Growth: 200.0%)
$33.74
(+35%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (149x PE), but valuation improves significantly next year (46x PE) as earnings recover.
Forward PE: 149.25 | Forward EPS (Implied): $0.17
Bull Case
$30.09
(+21%)
Analyst growth 15.0%, PE expands to 156.7
Base Case
$24.92
(0%)
Market implied 0.0%, PE stable at 149.3
Bear Case
$19.06
(-24%)
Severe decline -15.0%, PE contracts to 134.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 2:12 PM ET
Data refreshes hourly during market hours. Next update: 3:12 PM
Data refreshes hourly during market hours. Next update: 3:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SMTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$88 | 64 BUY |
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$562 | 45 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$177 | 56 HOLD |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$366 | 63 BUY |
|
RMD
ResMed Inc |
BUY
19 analysts |
$256 | 50 HOLD |
